<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Feola S</submitter><funding>Helsinki Institute of Life Science</funding><funding>Horizon 2020 Framework Programme</funding><pagination>E1660</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7352969</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(6)</volume><pubmed_abstract>According to the latest available data, cancer is the second leading cause of death, highlighting the need for novel cancer therapeutic approaches. In this context, immunotherapy is emerging as a reliable first-line treatment for many cancers, particularly metastatic melanoma. Indeed, cancer immunotherapy has attracted great interest following the recent clinical approval of antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, that release the brakes of the immune system, thus reviving a field otherwise poorly explored. Cancer immunotherapy mainly relies on the generation and stimulation of cytotoxic CD8 T lymphocytes (CTLs) within the tumor microenvironment (TME), priming T cells and establishing efficient and durable anti-tumor immunity. Therefore, there is </pubmed_abstract><journal>Cancers</journal><pubmed_title>Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.</pubmed_title><pmcid>PMC7352969</pmcid><funding_grant_id>681219</funding_grant_id><funding_grant_id>none</funding_grant_id><pubmed_authors>Martins B</pubmed_authors><pubmed_authors>Cerullo V</pubmed_authors><pubmed_authors>Feola S</pubmed_authors><pubmed_authors>Chiaro J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.</name><description>According to the latest available data, cancer is the second leading cause of death, highlighting the need for novel cancer therapeutic approaches. In this context, immunotherapy is emerging as a reliable first-line treatment for many cancers, particularly metastatic melanoma. Indeed, cancer immunotherapy has attracted great interest following the recent clinical approval of antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, that release the brakes of the immune system, thus reviving a field otherwise poorly explored. Cancer immunotherapy mainly relies on the generation and stimulation of cytotoxic CD8 T lymphocytes (CTLs) within the tumor microenvironment (TME), priming T cells and establishing efficient and durable anti-tumor immunity. Therefore, there is </description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jun</publication><modification>2025-06-01T02:36:01.978Z</modification><creation>2020-11-19T16:52:18Z</creation></dates><accession>S-EPMC7352969</accession><cross_references><pubmed>32585818</pubmed><doi>10.3390/cancers12061660</doi></cross_references></HashMap>